Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
September 06 2017 - 4:05PM
Business Wire
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the development, manufacturing and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that Antony Mattessich,
Chief Executive Officer, will present at three upcoming investor
conferences in September:
- Morgan Stanley 15th Annual Global
Healthcare ConferenceFireside Chat: Monday, September 11, 2017
at 1:05 p.m. Eastern TimeGrand Hyatt New York Hotel, New York,
NY
- Rodman & Renshaw 19th Annual
Global Investment ConferencePresentation: Tuesday, September
12, 2017 at 2:10 p.m. Eastern TimeLotte New York Palace Hotel, New
York, NY
- Cantor Fitzgerald 2017 Global
Healthcare ConferencePresentation: Monday, September 25, 2017
at 3:35 p.m. Eastern TimeInterContinental New York Barclay Hotel,
New York, NY
Live audio webcasts of the presentations can be accessed through
the Calendar of Events section of the Company's website at
investors.ocutx.com. Replays of the webcasts will be available on
the Company's website for two weeks following each
presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary hydrogel platform technology. Ocular Therapeutix’s
lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for
intracanalicular use, has completed Phase 3 clinical development
for the treatment of ocular pain and inflammation following
ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3
clinical development for glaucoma and ocular hypertension. The
Company’s earlier stage assets include OTX-TIC, a sustained release
travoprost intracameral injection for the treatment of moderate to
severe glaucoma and ocular hypertension, as well as sustained
release intravitreal injections for the treatment of retinal
diseases. These injections include the development of OTX-TKI, a
tyrosine kinase inhibitor (TKI), and, in collaboration with
Regeneron, an extended release protein-based anti-vascular
endothelial growth factor (VEGF) trap. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906006428/en/
InvestorsBurns McClellanSteve Klass,
212-213-0006sklass@burnsmc.comorOcular TherapeutixGeorge
MigauskyInterim Chief Financial
Officergmigausky@ocutx.comorMediaOcular TherapeutixScott
CorningVice President of Marketing & Commercial
Operationsscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024